Somaxon Pharmaceuticals Inc. and Procter & Gamble have partnered to co-promote Silenor, an insomnia treatment, to doctors and pharmacies. P&G will place 215 sales representatives in the U.S. to target primary-care doctors and high-prescribing physicians. This renewable deal lasts until 2012 and allows P&G to develop and market Silenor as an over-the-counter medication.
Read the full story
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.